Armstrong, A., Paul, C., Puig, L., Boehncke, W. H., Freeman, M., Torii, H., . . . Lebwohl, M. G. (2019). Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure. Dermatol Ther (Heidelb).
Style de citation ChicagoArmstrong, April, et al. "Safety of Ixekizumab Treatment for Up to 5 Years in Adult Patients With Moderate-to-Severe Psoriasis: Results From Greater Than 17,000 Patient-Years of Exposure." Dermatol Ther (Heidelb) 2019.
Style de citation MLAArmstrong, April, et al. "Safety of Ixekizumab Treatment for Up to 5 Years in Adult Patients With Moderate-to-Severe Psoriasis: Results From Greater Than 17,000 Patient-Years of Exposure." Dermatol Ther (Heidelb) 2019.